Application of bacillus subtilis fibrinolytic enzyme in treating bronchitis

A technology of Bacillus subtilis and bronchitis, applied in the application field of Bacillus subtilis fibrinolytic enzyme in the treatment of bronchitis drugs, can solve the problems of treating symptoms but not the root cause, chronic bronchitis cannot be cured, lack of chronic bronchitis treatment drugs, etc., to achieve cough relief good effect, good therapeutic effect

Pending Publication Date: 2019-07-23
WUHAN ZHENFU PHARMA CO LTD
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically, the main drugs are antibiotics and antitussive drugs, which treat the symptoms but not the root cause, and cannot cure chronic bronchitis
Therefore, there is a lack of a safe and effective drug for the treatment of chronic bronchitis in clinical practice.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bacillus subtilis fibrinolytic enzyme in treating bronchitis
  • Application of bacillus subtilis fibrinolytic enzyme in treating bronchitis
  • Application of bacillus subtilis fibrinolytic enzyme in treating bronchitis

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0016] 3. Preparation of Bacillus subtilis fibrinolytic enzyme powder

[0017] After the fermentation is finished, the fermented liquid is centrifuged by a tube centrifuge, concentrated by microfiltration and ultrafiltration to obtain a concentrated liquid of about 25 L. The concentrated solution is spray-dried to obtain the spray-dried powder of subtilis stalk fibrinolytic enzyme raw material. The spray drying condition is that the inlet air temperature is 140°C and the outlet air temperature is 63-68°C;

[0018] 2. Implementation

Embodiment 1

[0020] 1. Animals used in the test: 25 rats, weighing 30-35g, were randomly divided into 5 groups, marked as normal group, model group, low-dose test group, middle-dose test group, and high-dose test group;

[0021] 2. Sample preparation

[0022] Normal group: normal saline, once a day, 0.3ml each time;

[0023] Blank control group: normal saline, once a day, 0.3ml each time;

[0024] Low-dose test group: 500 IU subtilis fibrinolytic enzyme solution was prepared with physiological saline, once a day, 0.3ml each time, for 30 consecutive days;

[0025] Medium-dose test group: prepare 500 IU subtilis fibrinolytic enzyme solution with physiological saline, once a day, 0.3ml each time, for 30 consecutive days;

[0026] High-dose test group: 500 IU subtilis fibrinolytic enzyme solution was prepared with physiological saline, once a day, 0.3ml each time, for 30 consecutive days;

[0027] 3. Test method

[0028] The rats in the model group and the three test groups were all treate...

Embodiment 2

[0039] 1. Animals used in the test: 25 rats, weighing 30-35g, were randomly divided into 5 groups, marked as normal group, model group, low-dose test group, middle-dose test group, and high-dose test group;

[0040] 2. Sample preparation

[0041] Blank control group: normal saline;

[0042] Positive control group: dextromethorphan hydrobromide tablets (manufactured by Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., batch number H10900005), which were dissolved in normal saline to make a suspension with a concentration of 3 mg / ml and a dose of 35 mg / kg weight;

[0043] Low-dose test group: prepare subtilis plasmin solution with a concentration of 500IU with physiological saline, and the dose is 35mg / kg body weight / day;

[0044] Medium-dose test group: the subtilis plasmin solution with a concentration of 500 IU was prepared with physiological saline, and the dose was 35 mg / kg body weight / day;

[0045] High-dose test group: prepare 500 IU subtilis fibrinolytic enzyme ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses an application of a bacillus subtilis fibrinolytic enzyme in treating bronchitis. The bacillus subtilis fibrinolytic enzyme is prepared by fermenting by bacillus subtilis QK02 strain, the strain is preserved in China Center for Type Culture Collection, and the strain number is CCTCCNO:M203078. The bacillus subtilis fibrinolytic enzyme has a very good therapeutic effect on the bronchitis and has a good cough-stopping effect.

Description

technical field [0001] The invention relates to the field of bronchitis treatment. More specifically, the present invention relates to the application of Bacillus subtilis plasmin in treating bronchitis. Background technique [0002] Bronchitis refers to chronic non-specific inflammation of the trachea, bronchial mucosa and surrounding tissues caused by viral or bacterial infection. In addition, chronic stimuli such as air temperature, smog and dust, and polluted air from the external environment can also cause the disease. Self-smoking can also cause bronchospasm, mucous membrane variation, decreased ciliary movement, and increased mucus secretion, leading to chronic bronchitis. The main symptoms of chronic bronchitis are cough, nasal congestion, runny nose, sore throat and hoarseness, etc., which seriously affect the patient's health and daily life. Clinically, medicines are mainly antibiotics and antitussive drugs, which treat the symptoms but not the disease, and cann...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/48A61P11/00A61P11/14
CPCA61K38/482C12Y304/21062A61P11/00A61P11/14
Inventor 王业富董艳山范青云胡坤坤胡定邦
Owner WUHAN ZHENFU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap